A new immunotherapy drug has demonstrated early promise in a recent prostate cancer clinical trial. The drug, called VIR-5500, is a "masked T-cell engager". This type of immunotherapy ignites our own ...

Researchers at Texas A&M Health have identified a molecular mechanism that increases cholesterol levels inside prostate ...

RNA cancer vaccines have the potential to significantly boost the immune system’s ability to fight and eliminate tumors.

Key takeawaysResearchers and scientists have engineered a new class of supercharged T cells that are stronger, longer-lasting ...

Johnson & Johnson (NYSE:JNJ) has entered a clinical supply agreement with GI Innovation to test a bispecific immunotherapy combination in prostate cancer. The collaboration focuses on evaluating J&J’s ...

News, features, and commentary about cancer-related issues ...

Developing the system required careful fine-tuning. Too much stimulation can wear out immune cells, while too little allows them to lose function. The researchers optimized the strength of activation ...

UCLA and Stanford Medicine researchers, in collaboration with scientists from the University of Utah and Columbia University, ...

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...

Researchers at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Tisch Cancer Center have discovered a biological pathway that helps explain why some bladder cancers do not respond well ...